Boyun Pharmaceutical
Latest round
- Series C
Last raised
- Jan 2022
Total raised
- $130M
Investors
- 5
About Boyun Pharmaceutical
Based in California, US, and founded in 2015, Boyun Pharmaceutical is a biopharmaceutical company that focuses on the development and industrialization of new ophthalmic drugs. Boyun Pharmaceutical offers new ophthalmic drugs for the treatment of ophthalmic diseases like ophthalmic surface, fundus, and glaucoma, which covers 2 indications of international multi-center clinical phase III.
Who invested in Boyun Pharmaceutical
5 investors across 1 round
See all investors in Boyun Pharmaceutical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jan 1, 2022
Amount
$130M
Investors
Questions about Boyun Pharmaceutical
Who invested in Boyun Pharmaceutical?
Boyun Pharmaceutical has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Boyun Pharmaceutical raised?
Boyun Pharmaceutical has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Boyun Pharmaceutical last raise money?
Boyun Pharmaceutical's most recent round on record is a Series C, in Jan 2022.
What does Boyun Pharmaceutical do?
Based in California, US, and founded in 2015, Boyun Pharmaceutical is a biopharmaceutical company that focuses on the development and industrialization of new ophthalmic drugs.
Where is Boyun Pharmaceutical headquartered?
Boyun Pharmaceutical is headquartered in US.
Which VCs invest in companies like Boyun Pharmaceutical?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Boyun Pharmaceutical's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Boyun Pharmaceutical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.